Akero Therapeutics, Inc. (AKRO)

Market Cap	3.69B
Revenue (ttm)	n/a
Net Income (ttm)	-283.96M
Shares Out	79.99M
EPS (ttm)	-3.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	644,604
Open	46.40
Previous Close	46.41
Day's Range	46.06 - 46.87
52-Week Range	21.34 - 58.40
Beta	-0.29
Analysts	Strong Buy
Price Target	80.38 (+74.36%)
Earnings Date	Nov 7, 2025

About AKRO

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 63
• Stock Exchange: NASDAQ
• Ticker Symbol: AKRO
• Website: https://akerotx.com

Analyst Summary

According to 8 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price target is $80.38, which is an increase of 74.36% from the latest price.

Price Target

$80.38

(74.36% upside)

Analyst Consensus: Strong Buy